Biotechnology

Found 11,878 articles

• MediciNova Announces Closing of Underwritten Public Offering of Common Stock

  2/13/2018

  In addition, MediciNova has granted the underwriters a 30-day option to purchase up to an additional 662,983 shares of common stock at the public offering price, less underwriting discounts and commissions.

• Catalyst Biosciences Announces Proposed Public Offering of Common Stock - Feb. 13, 2018

  2/13/2018

  All of the shares in the offering are to be sold by the Company.

• Affimed Announces Proposed Public Offering of Common Stock

  2/13/2018

  All of the shares in the offering will be sold by Affimed.

• Propanc Biopharma Provides Shareholder Update and Goals for 2018

  2/13/2018

  Since the beginning of 2017, the Company has initiated and completed a number of activities.

• Catalyst Biosciences Announces Pricing of Public Offering of Common Stock - Feb. 13, 2018

  2/13/2018

  Additionally, the Company has granted the underwriters an option to purchase up to an additional 441,176 shares of its common stock, at the price to the public.

• Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock

  2/13/2018

  Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

• Daré Bioscience to Raise Approximately $10.25M

  2/13/2018

  The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

• Affimed Announces Pricing of Public Offering of Common Stock

  2/13/2018

  The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

• Conversion of FIT Biotech Oy's Convertible Capital Notes Into Shares - Feb. 13, 2018

  2/13/2018

  The Board authorization is based on the Extraordinary General Meeting December 14, 2017.

• Largest Shareholder of ZIVO Bioscience to Extend Maturity Date of Its Convertible Debt

  2/13/2018

  In a related filing, HEP has agreed to extend the maturity date on $16.7 million of its Secured Convertible Promissory Note, including all related interest payments, from September 30, 2018 to April 1, 2019.

• Bionano Genomics Announces Global Launch of its New Direct Labeling Chemistry for Genome Mapping and Structural Variation Analysis - Feb. 13, 2018

  2/13/2018

  On 15 August 2017, Ossur initiated a share buy-back program.

• CTI BioPharma Announces Closing of Underwritten Public Offering of Common Stock

  2/13/2018

  The expected proceeds to CTI BioPharma from the offering are approximately $64.2M.

• Daré Bioscience Announces Proposed Public Offering of Common Stock

  2/13/2018

  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

• Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018

  2/13/2018

  Management will host a conference call and webcast discussion of the results and provide a general corporate update.

• CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

  2/13/2018

  CEL-SCI reported an operating loss of ($4,911,430) for the quarter ended December 31, 2017 versus an operating loss of ($4,938,008) for the quarter ended December 31, 2016.

• Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance

  2/13/2018

  For the quarter, revenue from continuing operations was $478.5 million, an increase of 2.5% from $466.8 million in the fourth quarter of 2016.

• Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call

  2/13/2018

  The management team will host a conference call on Wednesday, March 7, 2018, at 4:30 p.m. ET to discuss the company's financial results and recent developments.

• IntriCon Reports 2017 Fourth-Quarter and Full-Year Results

  2/13/2018

  For the 2017 fourth quarter, the company reported net sales of $22.2 million, up 25.2 percent from $17.7 million in the prior-year period.

• Invitae Reports Over 150% Volume and Over 170% Revenue Growth for 2017

  2/13/2018

  Invitae today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

• RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018

  2/13/2018

  To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: